Colombo: Researchers from Sri Jayewardenepura University, one of Sri Lanka’s top universities, have discovered that China’s Sinopharm Covid-19 vaccine is very effective against the Delta version, which has become the world’s prevalent variant.
“This vaccination was also proven to be particularly effective against the Delta variant. Antibody responses to the delta version and neutralising antibodies were comparable to those reported after a natural infection “On Monday, the university announced it on its website.
According to the study, 95% of people who received two doses of the Sinopharm vaccine developed antibodies that were similar to those of a naturally infected Covid-19 person, according to the Xinhua news agency.
According to the Xinhua news agency, the study found that two doses of Sinopharm vaccine produced neutralising antibodies in 81.25 percent of participants, and that these antibody levels were equivalent to what would occur after surviving a normal Covid-19 infection.
Prof. Neelika Malavige, head of the Immunology and Molecular Medicine Department at Sri Jayewardenepura University, and her colleague Dr. Chandima Jeewandara were part of the research team, as were Oxford University academics Prof. Graham Ogg and Prof. Alain Townsend.
Prof. Neelika stated that Sinopharm is the most widely utilised vaccine currently being rolled out in Sri Lanka due to the country’s stockpile.
To date, 4.63 million Sri Lankans have gotten the first dosage of the Sinopharm Covid-19 vaccine, with another 1.29 million receiving the second dose. There hasn’t been a single example of a serious side effect linked to the immunisation.
Prof. Malavige stated that this is the first study of its kind to be published in the world, and that experts examined the immune system from every available angle from the Sinopharm shot.
The vaccine was also tested against the virus’s Alpha and Beta versions, as well as the original virus.
“The upshot of this investigation is that the Sinopharm vaccine elicits similar levels of antibody responses as patients who have been naturally infected with Delta and other variations, which is extremely good,” Prof. Malavige stated.
“98 percent of those aged 20 to 40 acquired antibodies, whereas 93 percent of those aged 60 and up developed antibodies. This is unsurprising given that elderly persons are less likely to respond to immunizations “Added the Professor.
She stated that this Sinopharm data had never been made public before, and that such real-world evidence was critical in boosting vaccine confidence both domestically and internationally.